{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:58:31Z","timestamp":1788346711155,"version":"build-2803163510"},"reference-count":85,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III (ISCIII)","award":["DTS22\/00071"],"award-info":[{"award-number":["DTS22\/00071"]}]},{"name":"European Union","award":["DTS22\/00071"],"award-info":[{"award-number":["DTS22\/00071"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Nanotechnology is transforming therapeutics for brain disorders, especially in developing drug delivery systems. Intrathecal immunoselective nanopheresis with soluble monoclonal antibodies represents an innovative approach in the realm of drug delivery systems for Central Nervous System conditions, especially for targeting soluble beta-amyloid in Alzheimer\u2019s disease. This review delves into the concept of intrathecal immunoselective nanopheresis. It provides an overall description of devices to perform this technique while discussing the nanotechnology behind its mechanism of action, its potential advantages, and clinical implications. By exploring current research and advancements, we aim to provide a comprehensive understanding of this novel method, addressing the critical questions of what it is, how it works, why it is needed, and when it should be applied. Special attention is given to patient selection and the optimal timing for therapy initiation in Alzheimer\u2019s, coinciding with the peak accumulation of amyloid oligomers in the early stages. Potential limitations and alternative targets beyond beta-amyloid and future perspectives for immunoselective nanopheresis are also described.<\/jats:p>","DOI":"10.3390\/ijms251910632","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T11:29:24Z","timestamp":1727868564000},"page":"10632","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intrathecal Immunoselective Nanopheresis for Alzheimer\u2019s Disease: What and How? Why and When?"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5218-0774","authenticated-orcid":false,"given":"Manuel","family":"Menendez-Gonzalez","sequence":"first","affiliation":[{"name":"Departamento de Medicina, Facultad de Ciencias de la Salud, Universidad de Oviedo, ES-33006 Oviedo, Spain"},{"name":"Hospital Universitario Central de Asturias, Servicio de Neurolog\u00eda, ES-33011 Oviedo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), ES-33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd725","article-title":"Drug and gene targeting to the brain with molecular Trojan horses","volume":"1","author":"Pardridge","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bors, L.A., and Erd\u0151, F. (2019). Overcoming the Blood\u2013Brain Barrier. Challenges and Tricks for CNS Drug Delivery. Sci. Pharm., 87.","DOI":"10.3390\/scipharm87010006"},{"key":"ref_5","first-page":"1037","article-title":"Blood-brain barrier transport of cytokines: A mechanism for neuropathology","volume":"9","author":"Banks","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"La Barbera, L., Mauri, E., D\u2019amelio, M., and Gori, M. (2022). Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer\u2019s disease: Current trends and future perspectives. Front. Neurosci., 16.","DOI":"10.3389\/fnins.2022.939855"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/mds.27722","article-title":"Focused ultrasound opening of the blood\u2013brain barrier for treatment of Parkinson\u2019s disease","volume":"34","author":"LeWitt","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","article-title":"Blood-brain barrier breakdown in the aging human hippocampus","volume":"85","author":"Montagne","year":"2015","journal-title":"Neuron"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sharma, C., Woo, H., and Kim, S.R. (2022). Addressing Blood\u2013Brain Barrier Impairment in Alzheimer\u2019s Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10040742"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev.pharmtox.47.120505.105237","article-title":"Drug targeting to the brain","volume":"47","author":"Gaillard","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","article-title":"Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management","volume":"367","author":"Singh","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_13","first-page":"100548","article-title":"Micro\/nanosystems for controllable drug delivery to the brain","volume":"5","author":"Tian","year":"2024","journal-title":"Innov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-030-55035-6_13","article-title":"Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer\u2019s Disease","volume":"Volume 1286","author":"Guest","year":"2021","journal-title":"Reviews on New Drug Targets in Age-Related Disorders"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Samipour, S., Setoodeh, P., Rahimpour, E., and Rahimpour, M.R. (2024). Functional nanoporous membranes for drug delivery. Current Trends and Future Developments on (Bio-) Membranes, Elsevier.","DOI":"10.1016\/B978-0-323-90258-8.00023-7"},{"key":"ref_16","unstructured":"Tang, Y., and Dawn, B. (2015). Exosome-Based translational nanomedicine: The therapeutic potential for drug delivery. Mesenchymal Stem Cell Derived Exosomes, Academic Press."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Teleanu, R.I., Preda, M.D., Niculescu, A.-G., Vlad\u00e2cenco, O., Radu, C.I., Grumezescu, A.M., and Teleanu, D.M. (2022). Current Strategies to Enhance Delivery of Drugs across the Blood\u2013Brain Barrier. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14050987"},{"key":"ref_18","unstructured":"Azar, A.T. (2021). Strategies-Based Intrathecal Targeted Drug Delivery System for Effective Therapy, Modeling, and Controlled Release Action. Modeling and Control of Drug Delivery Systems, Academic Press."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bjae.2019.11.002","article-title":"Complications associated with intrathecal drug delivery systems","volume":"20","author":"Delhaas","year":"2019","journal-title":"BJA Educ."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/ner.13325","article-title":"Adverse Events and Complications Associated With Intrathecal Drug Delivery Systems: Insights From the Manufacturer and User Facility Device Experience (MAUDE) Database","volume":"24","author":"Goel","year":"2020","journal-title":"Neuromodulation: Technol. Neural Interface"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Manuel, M.G., Tamba, B.I., Leclere, M., Mabrouk, M., Schreiner, T.G., Ciobanu, R., and Cristina, T.Z. (2023). Intrathecal pseudodelivery of drugs in the therapy of neurodegenerative diseases: Rationale, basis, and potential applications. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030768"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.desal.2004.01.007","article-title":"A comprehensive review of nanofiltration membranes: Treatment, pretreatment, modelling, and atomic force microscopy","volume":"170","author":"Hilal","year":"2004","journal-title":"Desalination"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Shukla, A.K., Alam, J., and Alhoshan, M. (2022). Recent advancements in polyphenylsulfone membrane modification methods for separation applications. Membranes, 12.","DOI":"10.3390\/membranes12020247"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.desal.2013.06.016","article-title":"A review on membrane fabrication: Structure, properties, and performance relationship","volume":"326","author":"Lalia","year":"2013","journal-title":"Desalination"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2147\/IJN.S402954","article-title":"Potential biomedical limitations of graphene nanomaterials","volume":"18","author":"Ban","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"ref_26","first-page":"287","article-title":"Health technology assessment of pathogen reduction technologies applied to plasma for clinical use","volume":"14","author":"Cicchetti","year":"2016","journal-title":"Blood Transfus."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Peydayesh, M. (2022). Nanofiltration membranes: Recent advances and environmental applications. Membranes, 12.","DOI":"10.3390\/books978-3-0365-4335-2"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Schreiner, T.G., Tamba, B.I., Mihai, C.T., L\u0151rinczi, A., Baibarac, M., Ciobanu, R.C., and Popescu, B.O. (2022). Nanoporous membranes for the filtration of proteins from biological fluids: Biocompatibility tests on cell cultures and suggested applications for the treatment of Alzheimer\u2019s disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195846"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Osama, L., Handal, H.T., El-Sayed, S.A.M., Elzayat, E.M., and Mabrouk, M. (2024). Fabrication and optimisation of alumina nanoporous membranes for drug delivery applications: A comparative study. Nanomaterials, 14.","DOI":"10.3390\/nano14131078"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1073\/pnas.82.24.8729","article-title":"Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related","volume":"82","author":"Wong","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The path forward in Alzheimer\u2019s disease therapeutics: Reevaluating the amyloid cascade hypothesis","volume":"16","author":"Tolar","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Hillen, H. (2019). The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer\u2019s Disease. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.01154"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Tolar, M., Snyder, P., Abushakra, S., and Sabbagh, M. (2021). Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer\u2019s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126355"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic A\u03b2 oligomer and Alzheimer\u2019s disease: An emperor in need of clothes","volume":"15","author":"Benilova","year":"2012","journal-title":"Nat. Neurosci."},{"key":"ref_36","first-page":"e12589","article-title":"A\u03b2 oligomers peak in early stages of Alzheimer\u2019s disease preceding tau pathology","volume":"16","author":"Rehn","year":"2024","journal-title":"Alzheimer\u2019s Dementia: Diagn. Assess. Dis. Monit."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","article-title":"Brain to Plasma Amyloid-\u03b2 Efflux: A Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer\u2019s Disease","volume":"295","author":"DeMattos","year":"2002","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/alz.12137","article-title":"A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer\u2019s disease: Primary results of the AMBAR Study","volume":"16","author":"Boada","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nrl.2014.02.003","article-title":"Treatment of Alzheimer\u2019s disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study","volume":"31","author":"Boada","year":"2016","journal-title":"Neurologia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/alz.12477","article-title":"Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer\u2019s disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study","volume":"18","author":"Boada","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tmrv.2022.09.005","article-title":"Plasma exchange in Alzheimer\u2019s disease","volume":"37","author":"Rohrer","year":"2023","journal-title":"Transfus. Med. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ramirez, S., Koerich, S., Astudillo, N., De Gregorio, N., Al-Lahham, R., Allison, T., Rocha, N.P., Wang, F., and Soto, C. (2023). Plasma exchange reduces A\u03b2 levels in plasma and decreases amyloid plaques in the brain in a mouse model of Alzheimer\u2019s disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242317087"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3233\/JAD-190087","article-title":"Influx of tau and amyloid-\u03b2 proteins into the blood during hemodialysis as a therapeutic extracorporeal blood amyloid-\u03b2 removal system for Alzheimer\u2019s disease","volume":"69","author":"Kitaguchi","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10047-015-0878-1","article-title":"Toward the treatment for Alzheimer\u2019s disease: Adsorption is the primary mechanism of removing amyloid \u03b2 protein with hollow-fiber dialyzers of the suitable materials, polysulfone and polymethyl methacrylate","volume":"19","author":"Kawaguchi","year":"2016","journal-title":"J. Artif. Organs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10047-017-1012-3","article-title":"Adsorptive filtration systems for effective removal of blood amyloid \u03b2: A potential therapy for Alzheimer\u2019s disease","volume":"21","author":"Kitaguchi","year":"2018","journal-title":"J. Artif. Organs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10047-012-0675-z","article-title":"A potential therapeutic system for Alzheimer\u2019s disease using adsorbents with alkyl ligands for removal of blood amyloid \u03b2","volume":"16","author":"Kawaguchi","year":"2013","journal-title":"J. Artif. Organs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2174\/138161211795164112","article-title":"Immunotherapy for Alzheimer\u2019s disease: Rational basis in ongoing clinical trials","volume":"17","author":"Vega","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after A\u03b242 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jconrel.2024.09.012","article-title":"Amyloid-\u03b2-targeting immunotherapies for Alzheimer\u2019s disease","volume":"375","author":"Jin","year":"2024","journal-title":"J. Contr. Release"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Islam, R., Rabbi, A., Hossain, T., Sultana, S., and Uddin, S. (2024). Mechanistic Approach to Immunity and Immunotherapy of Alzheimer\u2019s Disease: A Review. ACS Chem. Neurosci., in press.","DOI":"10.1021\/acschemneuro.4c00360"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez-Gonz\u00e1lez, M., Padilla-Zambrano, H.S., and Alvarez, G. (2018). Targeting beta-amyloid at the CSF. Front. Aging Neurosci., 10.","DOI":"10.3389\/fnagi.2018.00100"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Schreiner, T.G., Men\u00e9ndez-Gonz\u00e1lez, M., and Popescu, B.O. (2022). The \u201cCerebrospinal Fluid Sink Therapeutic Strategy\u201d in Alzheimer\u2019s Disease\u2014From theory to design of applied systems. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071509"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/17434440.2023.2181695","article-title":"Mechanical filtration of the cerebrospinal fluid: Procedures, systems, and applications","volume":"20","year":"2023","journal-title":"Expert Rev. Med. Devices"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez-Gonz\u00e1lez, M. (2023). Liquorpheresis: Cerebrospinal Fluid Filtration to Treat CNS Conditions, Springer.","DOI":"10.1007\/978-3-031-43482-2"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF02191143","article-title":"Liquorpheresis (CSF-filtration): An effective treatment in acute and chronic severe autoimmune polyradiculoneuritis (Guillain-Barr\u00e9 syndrome)","volume":"241","author":"Wollinsky","year":"1991","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.sc.3100857","article-title":"Liquorpheresis (CSF filtration) in familial amyotrophic lateral sclerosis","volume":"37","author":"Finsterer","year":"1999","journal-title":"Spinal Cord"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.wneu.2024.04.049","article-title":"The potential of liquorpheresis to treat leptomeningeal disease","volume":"187","author":"Lu","year":"2024","journal-title":"World Neurosurg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF02191142","article-title":"Liquorpheresis eliminates blocking factors from cerebrospinal fluid in polyradiculoneuritis (Guillain-Barr\u00e9 syndrome)","volume":"241","author":"Wollinsky","year":"1991","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40265-022-01757-5","article-title":"Treatment of cryptococcal meningitis: How have we got here and where are we going?","volume":"82","author":"Ngan","year":"2022","journal-title":"Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/infdis\/jiy286","article-title":"Novel treatment of cryptococcal meningitis via neurapheresis therapy","volume":"218","author":"Smilnak","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12975-022-00995-9","article-title":"Targeting hemoglobin to reduce delayed cerebral ischemia after subarachnoid hemorrhage","volume":"13","author":"Zeineddine","year":"2022","journal-title":"Transl. Stroke Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1161\/STROKEAHA.119.025399","article-title":"Prospective trial of cerebrospinal fluid filtration after aneurysmal subarachnoid hemorrhage via lumbar catheter (PILLAR)","volume":"50","author":"Blackburn","year":"2019","journal-title":"Stroke"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez-Gonz\u00e1lez, M., and Gasparovic, C. (2019). Albumin exchange in Alzheimer\u2019s disease: Might CSF be an alternative route to plasma?. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.01036"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Coto-Vilcapoma, A.M., Castilla-Silgado, J., Fern\u00e1ndez-Garc\u00eda, B., Pinto-Hern\u00e1ndez, P., Cipriani, R., Capetillo-Zarate, E., Men\u00e9ndez-Gonz\u00e1lez, M., \u00c1lvarez-Vega, M., and Tom\u00e1s-Zapico, C. (2022). New, fully implantable device for selective clearance of CSF-target molecules: Proof of concept in a murine model of Alzheimer\u2019s disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169256"},{"key":"ref_70","unstructured":"Coto-Vilcapoma, A. (2024). Nanof\u00e9resis Inmunoselectiva de A\u03b2 en el L\u00edquido Cefalorraqu\u00eddeo Como Tratamiento de la Enfermedad de Alzheimer. [Ph.D. Thesis, Universidad de Oviedo]."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e12377","DOI":"10.1002\/trc2.12377","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_72","unstructured":"P\u00e9rez-Mart\u00edn, E., Coto-Vilcapoma, A., Vega, J.A., and \u00c1lvarez, V. (2024). Implantable device for intrathecal pseudodelivery of immunotherapies. J. Prev. Alzheimer\u2019s Dis., in press."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"eadk1822","DOI":"10.1126\/scisignal.adk1822","article-title":"The dopaminergic system promotes neprilysin-mediated degradation of amyloid-\u03b2 in the brain","volume":"17","author":"Watamura","year":"2024","journal-title":"Sci. Signal."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e230009","DOI":"10.1148\/rg.230009","article-title":"Amyloid-related imaging abnormalities in Alzheimer disease treated with anti-amyloid-\u03b2 therapy","volume":"43","author":"Agarwal","year":"2023","journal-title":"Radiographics"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Schreiner, T.G., Adam, M., Popescu, B.O., Szilagyi, A., Stanciu, G.D., Tamba, B.I., and Ciobanu, R.C. (2023). A Nanostructured Protein Filtration Device for Possible Use in the Treatment of Alzheimer\u2019s Disease\u2014Concept and Feasibility after In Vivo Tests. Bioengineering, 10.","DOI":"10.3390\/bioengineering10111303"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: An update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: Risk, mechanisms, and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","article-title":"Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance","volume":"3","author":"Castellano","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_81","first-page":"30373","article-title":"Function, therapeutic potential, and cell biology of BACE proteases: Current status and future prospects","volume":"289","author":"Vassar","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","article-title":"Targeting the beta secretase BACE1 for Alzheimer\u2019s disease therapy","volume":"13","author":"Yan","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_83","first-page":"a006346","article-title":"Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature","volume":"2","author":"Rogers","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: Current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nurt.2008.05.001","article-title":"Therapeutics for Alzheimer\u2019s disease based on the metal hypothesis","volume":"5","author":"Bush","year":"2008","journal-title":"Neurotherapeutics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10632\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:09:25Z","timestamp":1760112565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":85,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ijms251910632"],"URL":"https:\/\/doi.org\/10.3390\/ijms251910632","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]}}}